| Autor: |
Cross HS; Institute of Pathophysiology, University of Vienna Medical School, Währinger Gürtel 18-20, A-1090 Vienna, Austria. heide.cross@akh-wien.ac.at, Kállay E, Farhan H, Weiland T, Manhardt T |
| Jazyk: |
angličtina |
| Zdroj: |
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer [Recent Results Cancer Res] 2003; Vol. 164, pp. 413-25. |
| DOI: |
10.1007/978-3-642-55580-0_30 |
| Abstrakt: |
Though 1,25-dihydroxyvitamin D3 (1,25-D3) as well as some vitamin D analogs have an antimitotic as well as a differentiating action, therapeutic application in tumor patients is still precluded due to their hypercalcemic action at the necessary concentration. Our observation that early during progression, colon tumor cells express CYP27B1, the enzyme essential for 1,25-D3 synthesis, as well as the vitamin D receptor (VDR) at a higher level than normal colon cells led to the speculation that, by induction of this expression, a physiological defense against tumor progression could be activated and enhanced. In some Asian countries where soy products are a main staple, prostate and breast tumor incidence is extremely low. We speculated that this could be due to regulation of CYP enzymes by phytoestrogens present in soy such as genistein. In prostate tumor cells, the 1,25-dihydroxyvitamin D3 catabolizing enzyme CYP24 is frequently highly expressed. We were able to demonstrate that genistein down-regulates expression of CYP24 to almost nil, which would result in enhancement of local 1,25-D3 levels and improved mitotic control of tumor cells. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
